Raloxifene/Colecalciferol- Alvogen Korea

Drug Profile

Raloxifene/Colecalciferol- Alvogen Korea

Alternative Names: DP R213; Raloxifene/Cholecalciferol

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alvogen Korea
  • Class Adjuvants; Antineoplastics; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Stilbenes; Vitamin D analogues
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoporosis

Most Recent Events

  • 29 Mar 2017 Alvogen Korea completes a phase-I trial in Osteoporosis (In volunteers) in South Korea (NCT03010267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top